NRX Pharmaceuticals Files 8-K
Ticker: NRXPW · Form: 8-K · Filed: Mar 21, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Mar 21, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, financials
TL;DR
NRX Pharma filed an 8-K on 3/21/24 covering shareholder votes and financials.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on March 21, 2024, reporting on the submission of matters to a vote of security holders, Regulation FD disclosures, and financial statements. The company, formerly known as Big Rock Partners Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations industry.
Why It Matters
This filing provides updates on corporate actions and financial reporting for NRX Pharmaceuticals, which could impact investor understanding of the company's status and future direction.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former Company Name
- March 21, 2024 (date) — Filing Date
FAQ
What are the main items reported in this 8-K filing?
This 8-K filing reports on the submission of matters to a vote of security holders, Regulation FD disclosures, and financial statements and exhibits.
What was NRX Pharmaceuticals, Inc. formerly known as?
NRX Pharmaceuticals, Inc. was formerly known as Big Rock Partners Acquisition Corp.
In which state is NRX Pharmaceuticals, Inc. incorporated?
NRX Pharmaceuticals, Inc. is incorporated in Delaware.
What is the Standard Industrial Classification code for NRX Pharmaceuticals, Inc.?
The Standard Industrial Classification code for NRX Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 21, 2024.
Filing Stats: 809 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2024-03-21 17:09:09
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Mar
Filing Documents
- tm2333863d6_8k.htm (8-K) — 31KB
- tm2333863d6_ex99-1.htm (EX-99.1) — 6KB
- 0001104659-24-037389.txt ( ) — 253KB
- nrxp-20240321.xsd (EX-101.SCH) — 3KB
- nrxp-20240321_def.xml (EX-101.DEF) — 26KB
- nrxp-20240321_lab.xml (EX-101.LAB) — 36KB
- nrxp-20240321_pre.xml (EX-101.PRE) — 25KB
- tm2333863d6_8k_htm.xml (XML) — 5KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. On March 21, 2024, NRx Pharmaceuticals, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting"). During the course of the Special Meeting, the Company's stockholders considered the proposal below. The final results of the vote regarding such proposal are set forth in the following table. Proposal 1. The Company's stockholders approved an amendment to the Company's Second Amended and Restated Certificate of Incorporation to effect, at the discretion of the Board of Directors of the Company (the "Board") but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company's stockholders at the Special Meeting, a reverse stock split of all of the outstanding shares of the Company's common stock, $0.001 par value per share, at a ratio in the range of 1-for-2 to 1-for-15, with such ratio to be determined by the Board in its discretion and included in a public announcement. The results of the voting were as follows: Votes For Votes Against Abstentions 53,597,974 2,441,255 742,125 By approving the foregoing proposal, the stockholders granted the Board discretion to implement a reverse stock split at a ratio within the approved range or to not effect any reverse stock split at all.The proposal is described in detail in the Company's definitive proxy statement for the Special Meeting, filed with the Securities and Exchange Commission on March 11, 2024, the relevant portions of which are incorporated herein by reference. The results reported above are final voting results. No other matters were considered or voted upon at the Special Meeting.
01
Item 7.01 Regulation FD Disclosure. On March 21, 2024, the Company issued a press release announcing the results of the Special Meeting. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Report. Exhibit No. Description 99.1 Press Release, dated March 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: March 21, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Chief Executive Officer